Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Biotechnology Healthcare|April 6, 2012
New approaches to treat cancer - what they can and cannot doNalân UtkuFuture Oncology (London, England)|December 14, 2011
Improving the outcomes: developing cancer therapeuticsNalân UtkuCurrent Opinion in Investigational Drugs (London, England : 2000)|May 25, 2007
T-cell immune response cDNA 7 in allograft rejection and inflammationNalân Utku, Thomas Heinemann, Edgar L MilfordDrug News & Perspectives|May 11, 2005
TIRC7 pathway as a target for preventing allograft rejectionAkihiko Tamura, Edgar L Milford, Nalân UtkuJournal of Gastrointestinal Oncology|September 21, 2020
A review of systemic therapy in biliary tract carcinomaHolger Jansen, Ulrich-Frank Pape, Nalân UtkuTransplant Immunology|December 2, 2006
TIRC7 is induced in rejected human kidneys and anti-TIRC7 mAb with FK506 prolongs survival of kidney allografts in ratsYusuke Kumamoto, Akihiko Tamura, Hans-Dieter Volk, et al.Cancer Letters|May 7, 2016
Tissue-infiltrating plasma cells are an important source of carboxylesterase 2 contributing to the therapeutic efficacy of prodrugsAnja A Kühl, Ulrike Erben, Constanze Cieluch, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2004
TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine responseNalân Utku, Anke Boerner, Antje Tomschegg, et al.Plos One|February 14, 2008
HLA-DR alpha 2 mediates negative signalling via binding to Tirc7 leading to anti-inflammatory and apoptotic effects in lymphocytes in vitro and in vivoGrit-Carsta Bulwin, Stephanie Wälter, Mirko Schlawinsky, et al.Cancers|October 30, 2020
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II StudyUlrich-Frank Pape, Stefan Kasper, Johannes Meiler, et al.Pageof 2